Global Allergy Immunotherapies Market is segmented By Treatment Type (Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT)), By Allergy Type (Allergic rhinitis, Allergic asthma, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029
Market Overview
The "Global Allergy Immunotherapies Market" is predicted to reach at a high CAGR of 10.4% during the forecast period (2022-2029)
Allergy immunotherapy is a medical treatment for allergic reactions to allergens, including various foods, drugs, bee venom, grass pollens, and house dust mites. It alters the immune system’s response by gradually increasing the doses of the allergen.
Source: DataM Intelligence Analysis (2020)
Market Dynamics
The increasing prevalence of allergic rhinitis is expected to drive the market's growth.
According to the Asthma and Allergy Foundation of America, allergic rhinitis (AR) is an IgE inflammatory response in the nasal mucosa following exposure to allergens that the subject is sensitized to symptoms mainly include rhino rhea and nasal congestion, sneezing, pruritus, and eye signs such as redness and itching/watery eyes. Besides physical discomfort, AR patients often present sleep disturbances, school absenteeism, impaired workability and quality of life. It affects 5.2 million of the children population and 19.2 million of the adult population. In addition, in 2018, white children were more likely to have hay fever than Black children and the same triggers for indoor/outdoor allergies also often cause eye allergies. As per the Canadian Allergy, Asthma, and Immunology Foundation, allergic rhinitis affects nearly 20 to 25% of the Canadian population.
Complex allergies with high morbidity are burden on the healthcare system, hence driving R&D in allergy immunotherapies market for the launch of novel therapies. In addition, rising air pollution, both indoors and outdoors, has led to increase in the prevalence of asthma and allergic disorders of the respiratory tract. According to the Asthma and Allergy Foundation of America (AAFA) more than 25 million allergies are caused due to increased pollen counts.
Thus, with rise in the demand for allergy immunotherapies, major companies are focused on the development of innovative immunotherapy products.
Increasing number of pipeline products is expected to boost the market growth over the forecast period
Increasing number of pipeline immunotherapy products for treatment of allergy is expected to boost the growth of the market and provide robust opportunties for several companies over the forecast period. Some of the researchers have tested sublingual immunotherapy for a variety of food allergies, including milk, peanut, kiwi, and peach allergies. These studies has obsevered that the treatment is beneficial when the patient takes medication on a regular basis. However, the effect of therapy post completion of treatment is yet to be determined.
COVID-19 Impact Analysis
COVID-19 pandemic has caused dramatic changes in allergy and immunology services. During the pandemic, urgent adjustments in health care, including the implementation of remote services, have been required to prevent the spread of the virus by providing social distance measures. International guidelines in asthma and allergy have been updated due to the COVID-19 pandemic, which has caused dramatic changes in allergy and immunology services. Telemedicine reduced allergy and clinical immunology services, and delay of elective procedures have been encouraged by guidelines to decrease face-to-face interactions. Continuation of asthma medications, including inhaled corticosteroids and oral corticosteroids if prescribed, the use of written asthma action plans and avoidance of nebulizers and spirometry are examples of other main recommendations. For instance, as per a recent survey, during the COVID-19 pandemic, only 11 and 25 respondents reported the continuation of oral challenge, skin testing, or blood testing in drug hypersensitivity and food allergy diagnosis, respectively. Other respondents postponed oral challenge or skin testing for drug/food allergy. Eighty-seven respondents (47%) continued desensitization in patients undergoing chemotherapy and with biological agent allergy. However, the situation is expected to improve gradually over the forecast period.
Segment Analysis
On the basis of treatment type, subcutaneous immunotherapy (SCIT) segment held the largest market share in allery immunotherapies market
The subcutaneous immunotherapy segment accounted for the largest market share in 2020. Subcutaneous immunotherapy the most effective and commonly used form of allergy immunotherapy. The therapy is useful in treating allergic rhinitis, asthma, and stinging insect hypersensitivity. Also, SCIT has been active in the management of more than one type of allergen. Subcutaneous immunotherapy (SCIT) is the standard method for treating patients with sensitizations to aeroallergens. However, immunotherapy can trigger severe systemic reactions if delivered inappropriately or to high-risk patients. In addition, the Canadian Society of Allergy and Clinical Immunology has done its first-ever study to review patients with systemic reactions to subcutaneous immunotherapy. Throughout the study, several best practice methods were employed to optimize subcutaneous delivery of immunotherapy extract and recorded per injection incidence rate for systemic reactions. Therefore recommendations in the CSACI Immunotherapy Manual have provided an appearance to standardizing prescriptions for SCIT to maximize immunotherapy efficacy and decrease the risk of systemic reactions, though similar studies in larger multicenter.
Source: DataM Intelligence Analysis (2020)
Geographical Analysis
Europe region holds the largest market share in the global allergy immunotherapies market
Europe dominated the market in 2020. The growth of allergy immunotherapies in Europe is benefited due to the increasing prevalence of allergic disorders, the strong presence of leading market players, and R&D for the development of effective and safer allergen-specific immunotherapy practices is expected to boost the market in the forecast period. Allergen immunotherapy (AIT) is the only perspective in which a vaccine is applied to patients allergic to the active principle in the vaccine. More than 150 million Europeans suffer from allergic disorders and expected that more than 50% of the population in this region would be affected by at least one form of allergy by 2025 owing to various factors, such as industrialization, urbanization, climate change, and pollution.
Source: DataM Intelligence Analysis (2020)
Competitive Landscape
The allergy immunotherapies market is highly competitive with presence several players in the market. Some of the key players which are contributing to the growth of the market include Merck KGaA, Stallergenes Greer plc , Allergy Therapeutics , Mylan N.V., ASIT Biotech, DBV Technologies SA, LETIPharma. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the allergy immunotherapies market globally. For instance, in October 2019, Stallergenes Greer Ltd. collaborated with Anergis, a Switzerland-based clinical-stage biopharma company, to initiate a research study focused on the evaluation of the second-generation contiguous overlapping peptides allergen immunotherapy for birch pollen allergy.
Allergy Immunotherapies Market Key Companies to Watch
Stallergenes Greer Ltd:
Overview:
Stallergenes Greer Ltd. is a global biopharmaceutical company headquartered in London, specializing in diagnosing and treating respiratory allergies through immunotherapy. Moreover, it is the parent company of GREER Laboratories, Inc. and Stallergenes S.A.S. Its core manufacturing facilities are located both in Europe and the USA.
Product Portfolio:
Stallergenes Greer Ltd has continuously set new standards for manufacturing allergen extracts in powdered, liquid, and freeze‐dried extract formulations. For instance, Named Patient Products (NPPs) are prepared according to the allergist’s prescription and the patient profile using a stock solution obtained via the extraction of allergens (pollen, house dust mites, mold).
Why Purchase the Report?
- Visualize the composition of the allergy immunotherapies market segmentation by treatment type, allergy type, distribution channel and region highlighting the key commercial assets and players.
- Identify commercial opportunities in allergy immunotherapies market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of allergy immunotherapies market- level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global allergy immunotherapies market report would provide an access to an approx.46 market data table, 46 figures and 180pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers